Rate My Professor mark abzug

Abzug directs clinical research on viral infections, infections in immunocompromised patients, and pediatric HIV infection. He participates in national collaborative clinical trials of antiviral therapies through the National Institutes of Health Collaborative Antiviral Study Group and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network. His clinical interests include perinatal infections, enterovirus infections, and infections in immunocompromised patients. He served as Principal Investigator on an NIH-funded grant (R29HD027692) from 1991 to 1997 studying enterovirus infections of the placenta and fetus. Abzug has contributed extensively to the literature, serving as an editor for Current Diagnosis and Treatment: Pediatrics, 27th edition (2025), and authoring chapters in Plotkin’s Vaccines, 8th edition (2024), Nelson Textbook of Pediatrics, 22nd edition (2024), Principles and Practice of Pediatric Infectious Diseases, 6th edition (2023), and Red Book: 2024 Report of the Committee on Infectious Diseases, 33rd edition (2024). Recent peer-reviewed publications include 'Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis' (Journal of the Pediatric Infectious Diseases Society, 2024), 'Guidance for prevention and management of COVID-19 in children and adolescents' (Journal of the Pediatric Infectious Diseases Society, 2024), and 'Adjunctive Diagnostic Studies Completed Following Detection of Candidemia in Children' (Journal of the Pediatric Infectious Diseases Society, 2023). Earlier works address enterovirus sepsis, acute flaccid myelitis, and HIV-related outcomes in youth.